A leading pharmaceutical company having 23 plants woridwide with regulatory approvals from USFDA, UK, MHRA, etc., with a turnover of more than $2.5 billion, invites applications for the following positions for its automated and most modem Injectable Formulation Units located at Hyderabad and Jedcherta (SEZ) to meet the existing and expansion requirements.
Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Fenofibrate Tablets, 48 mg and 145 mg. Fenofibrate Tablet is used to treat high level of cholesterol and triglyceride in the blood. Product is expected to be launched in Q1 FY16-17.
Aurobindo Pharma said it has received final approval from USFDA to manufacture and market generic version of Risedronate Sodium tablets, used in the treatment of Osteoporosis, in the American market.
Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Tramadol Hydrochloride Extended -release Tablets USP, 100 mg, 200 mg and 300 mg.
Hyderabad-based Aurobindo Pharma received the final approval from the US Food and Drug Administration to manufacture and market generic Aripiprazole tablets used for treatment of psychotic conditions in the American market. The approval is for the tablets in the strengths of 2mg, 5mg, 10mg, 15mg, 20mg and 30mg.
The US Food and Drug Administration (USFDA) has approved Aurobindo Pharma to market generic version of Prilosec delayed-release capsules used to treat ulcer.
Aurobindo Pharma got final approvals from the US FDA of azithromycin for injection USP, 500mg /vial and entacapone tablets. Azithromycin for injection USP, 500mg/vial is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Zithromax (azithromycin for injection) 500mg/vial of Pfizer, Inc. Azithromycin for injection, USP is a macrolide antibacterial drug indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions such as community-acquired pneumonia and pelvic inflammatory disease.
Aurobindo Pharma Limited (API) is a $2Bn + company with global operations in US, Europe, Asia. Africa, CIS etc. having multiple plants and markets spread across 3 continents with regulatory approvals from USFDA, UKMHRA etc.
API invites applicants, for the following positions for its automated and most modem Oral Solid Dosages Formulation Units.
Post: Technical Assistants, Executives
Aurobindo Pharma has received the final approval from the US Food and Drug Administration to manufacture and market Atracurium Besylate injection in single and multi-dose vials in the US market.
Aurobindo Pharma had gone public in 1995 by listing its shares in various stock exchanges in the country. The company is the market leader in semi-synthetic penicillin drugs. It has a presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc.